Published in Vaccine Weekly, February 14th, 2001
"BCG, the attenuated strain of Mycobacterium bovis, has been widely used as a vaccine against tuberculosis and is thus an important candidate as a live carrier for multiple antigens," wrote Eliane N. Miyaji and colleagues from the Instituto Butantan, Sao Paulo. "With the aim of developing a recombinant BCG (rBCG) vaccine against DPT, we analyzed the potential of CRM197, a mutated nontoxic derivative of diphtheria toxin, as the recombinant...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.